13 May '11, 2pm

Bone-grafting product Augment receives positive recommendation from FDA

Bone-grafting product Augment receives positive recommendation from FDA

Earlier this week, the panel indicated it had clinical concerns about Augment, posting a document which stated that it "still has concerns with the safety and overall risk/benefit of the device at this time, primarily due to the unanswered question of safety in regards to the potential for cancer formation versus and unproven benefit in the current standard for care." That document, and the impression it created that the FDA would vote against approving Augment, caused BioMimetic's stock price to drop by 34 percent on Tuesday, according to the Associated Press.

Full article: http://www.mnn.com/health/fitness-well-being/stories/bone...

Tweets